Ketamine analogues for treatment of thrombocytopenia

A compound represented by structural formulae I or II ##STR23## where:

• X is selected from one or more of the group
• hydrogen;
• halogen (F, Cl, Br, I);
• C.sub.1 -C.sub.6 -alkyl;
• and
• C.sub.1 -C.sub.6 -alkoxy;
• Y is selected from the group
• hydroxy;
• acyloxy;
• --NHR.sub.2 ;
• and
• --NR.sub.2 R.sub.3 ;
• provided that when the compound is represented by formula I, --NHR.sub.2 and --NR.sub.2 R.sub.3 are not --NH.sub.2 or --NHCH.sub.3 ;
• Z is selected from the group
• oxo;
• C.sub.2 -C.sub.4 -alkylenedioxy;
• and
• hydroxy;
• each R.sub.1 is independently selected from the group
• hydrogen;
• and
• C.sub.1 -C.sub.6 -alkyl;
• R.sub.2 and R.sub.3 are independently selected from the group
• unsubstituted or substituted C.sub.1 -C.sub.6 -alkyl;
• unsubstituted or substituted C.sub.6 -C.sub.14 -aryl;
• unsubstituted or substituted C.sub.1 -C.sub.6 -alkanoyl;
• unsubstituted or substituted C.sub.7 -C.sub.9 -aralkyl;
• and
• biotinoyl;
• wherein the substituents are selected from one or more of the group
• halo (F, Cl, Br, I);
• cyano;
• azido;
• nitro;
• amino;
• amidino;
• imino;
• aminomethyleneamino;
• iminomethylamino;
• guanidino;
• N.sup.G -- aminoguanidino;
• C.sub.1 -C.sub.6 -alkylamino;
• C.sub.2 -C.sub.10 -dialkylamino;
• C.sub.2 -C.sub.10 -alkylideneamino;
• C.sub.2 -C.sub.6 -acylamino;
• formylamino;
• N-(C.sub.1 -C.sub.6)-alkyl-N-(C.sub.1 -C.sub.6)-acylamino;
• C.sub.1 -C.sub.6 -alkylsulfonamido;
• N-(C.sub.1 - C.sub.6)alkyl-N-(C.sub.1 -C.sub.6)-alkylsulfonylamino;
• thioformamido;
• N-(C.sub.1 -C.sub.6)-alkyl-N-thioformylamino;
• thio(C.sub.1 -C.sub.6)-acylamino;
• N-(C.sub.1 -C.sub.6)-alkyl-N-thio(C.sub.1 -C.sub.6)-acylamino;
• thioureido;
• C.sub.2 -C.sub.6 alkylsulfinamido;
• N-(C.sub.1 -C.sub.6)-alkyl-N-(C.sub.1 -C.sub.6)-alkylsulfinylamino;
• N,N-di(C.sub.1 -C.sub.10)-acylamino;
• carboxy;
• C.sub.2 -C.sub.6 -carbalkoxy;
• formyl;
• C.sub.2 -C.sub.6 -alkylcarbonyl;
• formyloxy;
• C.sub.2 -C.sub.6 -alkanoyloxy;
• carbamoyl (carboxamido);
• N-(C.sub.1 -C.sub.6)-alkylcarboxamido;
• N,N-di(C.sub.1 -C.sub.10)-alkylcarboxamido;
• carbamoyloxy;
• N-(C.sub.1 -C.sub.6)-carbamoyloxy;
• N,N-di(C.sub.1 -C.sub.6)-alkylcarbamoyloxy;
• mercapto;
• C.sub.1 -C.sub.6 -alkylsulfinyl;
• C.sub.1 -C.sub.6 -alkylsulfonyl;
• C.sub.1 -C.sub.6 -alkylsulfonato;
• C.sub.1 -C.sub.6 -alkylthio;
• sulfonamido;
• N-(C.sub.1 -C.sub.6)-alkylsulfonamido;
• N,N-di(C.sub.1 -C.sub.6)-alkylsulfonamido;
• hydroxy;
• C.sub.1 -C.sub.6 -alkyloxy;
• C.sub.1 -C.sub.6 -alkyl optionally substituted with halo (F, Cl, Br, I), amino, C.sub.1 -C.sub.6 -alkylamino, carboxy, C.sub.1 -C.sub.4 -alkoxy, and hydroxy;
• C.sub.2 -C.sub.6 -alkenyl;
• C.sub.2 -C.sub.6 -alkynyl;
• C.sub.3 -C.sub.6 -cycloalkyl;
• C.sub.6 -C.sub.10 -aryl optionally substituted with halo (F, Cl, Br, I), amino, C.sub.1 -C.sub.6 -alkylamino, carboxy, C.sub.1 -C.sub.4 -alkoxy, and hydroxy;
• and heterocycloalkyl and heteroaryl having from 1 to 3 rings, each ring having from 0-3 hetero atoms selected from N, O, and S provided that at least one ring contains a heteroatom optionally substituted with halo (F, Cl, Br, I), amino, C.sub.1 -C.sub.6 -alkylamino, carboxy, C.sub.1 -C.sub.4 -alkoxy, and hydroxy;
• R.sub.2 and R.sub.3 taken together may form C.sub.4 -C.sub.8 -alkylene or C.sub.4 -C.sub.8 -oxydialkylene;
• and pharmaceutically acceptable salts thereof.